Prolonged proliferation and delayed senescence of the adipose-derived stem cells grown on the electrospun composite nanofiber co-encapsulated with TiO₂ nanoparticles and metformin-loaded mesoporous silica nanoparticles

This study was aimed to investigate the effects of the Poly-epsilon-Caprolactone/Gelatin nanofibers (PCL/GEL NFs) coencapsulated with TiO2 nanoparticles (nTiO2) and metformin-loaded mesoporous silica nanoparticles (MET@MSNs) on prolonging the in vitro expansion of human adipose-derived stem cells (hADSCs) without inducing cellular senescence and aging. FTIR, BET, FE-SEM, and TEM were applied to characterize the fabricated MET@MSNs and electrospun composite NFs. The presence of inorganic particles, nTiO2 and MSNs, in the scaffolds improved their mechanical properties and led to a more sustained release of MET with almost the lack of the initial burst release from nTiO2/MET@MSNs-loaded NFs. The enhanced adhesion, metabolic activity, and proliferation rate of the hADSCs grown on nTiO2/MET@MSNs-loaded NFs were demonstrated via FE-SEM images, MTT test and PicoGreen assay, respectively, over 28 days of culture. Furthermore, the irregular nanofibrillar structures and the impact of sustained release of MET led to a significant upregulation in the mRNA levels of autophagy (Atg-5, Atg-7, Atg-12, and Beclin-1) and stemness (Nanog3, Sox-2, and Oct-4) markers as well as a considerable down-regulation of p16INK4A senescence marker. Further, the upregulation of hTERT, enhanced activity of telomerase, and increased telomere length were more pronounced in the hADSCs cultured on nTiO2/MET@MSNs-loaded NFs as compared to other types of NFs. Overall, our findings demonstrated the potential of the fabricated nanocomposite platform for counteracting cellular senescence and achieving sufficient quantities of fresh hADSCs with preserved stemness for various stem cell-based regenerative medicine purposes.

Dergi

INTERNATIONAL JOURNAL OF PHARMACEUTICS

Yıl

2021

Cilt

604

ISSN

0378-5173

eISSN

1873-3476

DOI

10.1016/j.ijpharm.2021.120733

WoS UID

WOS:000677934200004